Overview

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the optimal tolerated regime of PEP005 for the treatment of actinic keratoses of the face or face and scalp.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peplin
Criteria
1. Male patients at least 18 years of age.

2. Post-menopausal female patients i.e., no menses for at least 12 consecutive months, or
without a uterus.

3. Four to eight clinically typical, visible and discrete AK lesions within a contiguous
25 cm2 treatment area on the face or face and scalp.

5. Ability to follow study instructions and likely to complete all study requirements.

6. Written informed consent has been obtained. 7. Agreement from the patient to allow
photographs of the selected AK treatment area to be taken and used as part of the study
data package.